Literature DB >> 23519772

Novel immunotherapies in GU malignancies.

Alexandra Drakaki1, David F McDermott.   

Abstract

Despite the development of several novel therapies in recent years, genitourinary (GU) malignancies remain associated with significant morbidity and mortality. An improved understanding of how the immune system responds to cancer has led to the clinical development of several targeted immunotherapies. Data from recent clinical trials suggests that these agents might improve the prognosis of patients with advanced GU malignancies. This review article will discuss the current state of immunotherapy and describe future directions in combination therapy and biomarker development for cancers of the kidney, bladder and prostate.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23519772     DOI： 10.1007/s11912-013-0306-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.945


  65 in total

Review 1.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Phase II study of sunitinib in patients with metastatic urothelial cancer.

Authors:  David J Gallagher; Matthew I Milowsky; Scott R Gerst; Nicole Ishill; Jamie Riches; Ashley Regazzi; Mary G Boyle; Alisa Trout; Anne-Marie Flaherty; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients.

Authors:  M Siebels; K Rohrmann; R Oberneder; M Stahler; N Haseke; J Beck; R Hofmann; M Kindler; P Kloepfer; C Stief
Journal:  World J Urol       Date:  2010-05-30       Impact factor: 4.226

5.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

7.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 8.  Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.

Authors:  Jeanny B Aragon-Ching; Kirsten M Williams; James L Gulley
Journal:  Front Biosci       Date:  2007-09-01

Review 9.  Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.

Authors:  Patricia A Tang; Daniel Y C Heng
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

10.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Authors:  G Fyfe; R I Fisher; S A Rosenberg; M Sznol; D R Parkinson; A C Louie
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.